Literature DB >> 15893108

Personality profiles of normal healthy research volunteers: a potential concern for clinical drug trial investigators?

Carl L Tishler1, Suzanne Bartholomae, Angel R Rhodes.   

Abstract

"Normal healthy research volunteers" (NHRVs) in Phase I clinical trials are utilized to provide precise pharmacokinetic information and subjective self-reports to help determine the initial drug dose for future Phase II, III, and IV trials, and accurate dose levels for future use in a patient population. Medical researchers rely on both objective pharmacokinetic and subjective data from NHRVs. Research shows that personality characteristics can influence these results in Phase I clinical trials. For example, extroverted personality characteristics have influenced the subjective reports and physiological experience of NHRVs. Second, subjective responses to placebos have been significantly greater in extroverted NHRVs than in introverted NHRVs. Third, in looking at Type-A and Type-B personality characteristics, NHRVs with Type-A Characteristics reported significantly more negative side effects to placebos than did people with Type-B characteristics. Fourth, NHRVs with high anxiety had more reports of adverse symptoms after drug administration than NHRVs with low anxiety. Further, it has been found that gastric emptying occurs more rapidly in people with high levels of neuroticism as compared to people with low levels of neuroticism. The authors suggest that personality and psychological characteristics of NHRVs can influence pharmacokinetic results and thus need to be addressed either in the statistical analysis or in the screening process for NHRV studies. Suggestions for further research and analysis are included, along with ideas for a national volunteer subject pool for NHRVs.

Entities:  

Mesh:

Year:  2005        PMID: 15893108     DOI: 10.1016/j.mehy.2005.01.018

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

1.  Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362.

Authors:  Susan E Cohn; Hongyu Jiang; J Allen McCutchan; Susan L Koletar; Robert L Murphy; Kevin R Robertson; Annabelle M de St Maurice; Judith S Currier; Paige L Williams
Journal:  AIDS Care       Date:  2011-06

2.  Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.

Authors:  David L Mount; Patricia Feeney; Anthony N Fabricatore; Mace Coday; Judy Bahnson; Robert Byington; Suzanne Phelan; Sharon Wilmoth; William C Knowler; Irene Hramiak; Kwame Osei; Mary Ellen Sweeney; Mark A Espeland
Journal:  Clin Trials       Date:  2009-09-08       Impact factor: 2.486

3.  Volunteerism and self-selection bias in human positron emission tomography neuroimaging research.

Authors:  Lynn M Oswald; Gary S Wand; Shijun Zhu; Victoria Selby
Journal:  Brain Imaging Behav       Date:  2013-06       Impact factor: 3.978

4.  Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events.

Authors:  Luis Almeida; Todd B Kashdan; Teresa Nunes; Rui Coelho; António Albino-Teixeira; Patrício Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 3.064

5.  Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trials.

Authors:  Eric G Devine; Kristina R Peebles; Valeria Martini
Journal:  Contemp Clin Trials Commun       Date:  2016-12-18

6.  Role of personality traits in reporting the development of adverse drug reactions: a prospective cohort study of the Estonian general population.

Authors:  Anu Realo; Henriët van Middendorp; Liisi Kööts-Ausmees; Jüri Allik; Andrea W M Evers
Journal:  BMJ Open       Date:  2018-07-10       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.